Y
Yanzhi Hsu
Researcher at Eli Lilly and Company
Publications - 39
Citations - 3412
Yanzhi Hsu is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Ramucirumab & Hepatocellular carcinoma. The author has an hindex of 14, co-authored 38 publications receiving 2588 citations. Previous affiliations of Yanzhi Hsu include ImClone Systems.
Papers
More filters
Journal ArticleDOI
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,G. Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,John Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M. Liepa,Ling Gao,Jonathan D. Schwartz,Josep Tabernero +24 more
TL;DR: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
Journal ArticleDOI
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X. Zhu,Yoon-Koo Kang,Chia Jui Yen,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Josep M. Llovet,Eric Assenat,Giovanni Brandi,Marc Pracht,Ho Yeong Lim,Kun-Ming Rau,Kenta Motomura,Izumi Ohno,Philippe Merle,Bruno Daniele,Dong Bok Shin,Guido Gerken,Christophe Borg,Jean-Baptiste Hiriart,Takuji Okusaka,Manabu Morimoto,Yanzhi Hsu,Paolo Abada,Masatoshi Kudo +24 more
TL;DR: Overall survival, progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, and time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8) were significantly improved in the ramucirumab group compared with the placebo group.
Journal ArticleDOI
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
Harry H. Yoon,Johanna C. Bendell,Fadi Braiteh,Irfan Firdaus,Philip A. Philip,Allen Lee Cohn,Nancy L. Lewis,D. M. Anderson,Edward Arrowsmith,Jonathan D. Schwartz,Ling Gao,Yanzhi Hsu,Yihuan Xu,David Ferry,Steven R. Alberts,Zev A. Wainberg +15 more
TL;DR: The addition of ramucirumab to front-line mFOLFOX6 did not improve PFS in the intent-to-treat (ITT) population, and an exploratory exposure-response analysis indicated that patients with higher ramucorumab exposure had longer OS.
Journal ArticleDOI
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
Andrew X. Zhu,Yoon-Koo Kang,Chia Jui Yen,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Eric Assenat,Giovanni Brandi,Ho Yeong Lim,Marc Pracht,Kun-Ming Rau,Philippe Merle,Kenta Motomura,Izumi Ohno,Bruno Daniele,Dongbok Shin,Guido Gerken,Paolo Abada,Yanzhi Hsu,Masatoshi Kudo +19 more
TL;DR: Patients with advanced HCC and elevated AFP have a poorer prognosis compared to the general HCC population, and need effective, well tolerated treatment options, and increased VEG...
Journal ArticleDOI
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
Charles S. Fuchs,Kei Muro,Jiri Tomasek,Eric Van Cutsem,Jae Yong Cho,Sang Cheul Oh,Howard Safran,György Bodoky,Ian Chau,Yasuhiro Shimada,Salah-Eddin Al-Batran,Rodolfo Passalacqua,Atsushi Ohtsu,Michael Emig,David Ferry,Kumari Chandrawansa,Yanzhi Hsu,Andreas Sashegyi,Astra M. Liepa,Hansjochen Wilke +19 more
TL;DR: The identified prognostic factors and the reported prognostic index may help clinical decision-making, patient stratification, and planning of future clinical studies.